Results

Total Results: 2,078 records

Showing results for "drugs".

361. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-medicine_research-protocol.pdf
     December 06, 2010 - Available therapies for RA include corticosteroids, oral disease-modifying antirheumatic drugs (DMARDs … Finally, very little is known about the benefits or risks of these drugs AMONG different patient subgroups … review did not include certolizumab pegol, golimumab, and tocilizumab (listed above), because these drugs … Golimumab Simponi® Tocililizumab Actemra®, RoActemrai® • Comparators: For all KQs: all review drugs

362. S89 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s89.pdf
     October 01, 2007 - Rapid Cycle Analysis Team Background: Rare but serious adverse events associated with vac- cines or drugs … meningococcal vaccine, drug safety (Med Care 2007;45: S89–S95) Concerns about the safety of vaccines and drugs … the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) and, for drugs … In addition, because drugs treat specific conditions, the pool of users for a new medication is limited … early detection of potential adverse events after the introduction of new vaccines, and possibly new drugs

363. S16 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s16.pdf
     October 01, 2007 - controlled trials (RCTs) remain the ac- cepted “gold standard” for determining the efficacy of new drugs … Follow-up and monitoring is designed to promote adherence to the drugs under study and to detect any … Drug coverage—Which bisphosphonate drugs should be included on a drug fomulary? … , quality of intervention Timing of intervention Cointerventions, quality of care Adherence (for drugs … Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute

364. For adults and children with asthma what is the effectiveness of the Buteyko Breathing method on reducing bronchodilator and inhaled steroid use and improving health status? | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/for-adults-and-children-with-asthma-what-is-the-effectiveness-of-the-buteyko-breathing-method-on-reducing-bronchodilator-and-inhaled-steroid-use-and-improving-health-status
     September 01, 2009 - no If yes, explain the specific technologies, devices, drugs, or interventions you would like to

365. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/for-all-patients-addressing-continuum-of-care-has-research-analysis-been-performed-to-promote-the-benefit-of-certified-nurse-case-managers-working-with-physicians-to-promote-appropriate-utilization-of-services-and-to-facilita
     March 10, 2009 - no If yes, explain the specific technologies, devices, drugs, or interventions you would like to

366. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/this-survey-would-about-early-warning-signs-of-multiple-sclerosis-which-i-documented-as-late-as-2-years-before-my-diagnosis-and-early-as-childhood-i-am-almost-finished-with-a-survey-i-spent-10-years-as-education-director-for-
     October 15, 2010 - no If yes, explain the specific technologies, devices, drugs, or interventions you would like to

367. Distributed Ambulatory Research in Therapeutics Network (DARTNet): Informing Practice and Improving Depression Care | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/depression-care-distributed-networks/abstract
     May 08, 2009 - Describe the patterns of use of antidepressants and combinations of other psychotropic drugs, both alone

368. Calcineurin Inhibitors for Kidney Transplant | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/calcineurin-inhibitor/research
     March 15, 2016 - Avoidance strategies based on de novo use of alternative immunosuppressive drugs are not widely studied

369. For patients with insomnia, how do commonly used medications compare for effectiveness and harms, including addictive potential. | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/for-patients-with-insomnia-how-do-commonly-used-medications-compare-for-effectiveness-and-harms-including-addictive-potential
     September 22, 2010 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

370. CARDIOVASCULAR (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cardiovascular-horizon-scan-high-impact-1412.pdf
     December 01, 2014 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … Cambridge (MA): Aegerion Pharmaceuticals, Inc.; 2012 Dec. 12 p. … Cambridge (MA): Aegerion Pharmaceuticals, Inc.; 2013 Apr. 12 p.

371. Who Uses Exenatide For Glucose Control in Diabetes Mellitus? A Retrospective Cohort Study of a New Therapy | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/diabetes-glucose-control/research
     August 04, 2010 - Exenatide, manufactured as Byetta by Amylin Pharmaceuticals, Inc. … Additionally, a separate, linkable file is available which includes pharmacy claims for prescription drugs … In Table 3 , we provide details about the other drugs for DM used by these patients. … Experts weigh in on promotion, prescription of off-label drugs. JAMA 2007;297:683-684.

372. Research White Paper Multinational Registries Addendum Registries for Evaluating Patient Outcomes Third Edition (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/multinational-registries-guide-3rd-ed-addendum-white-paper.pdf
     February 01, 2018 - focused on the outcomes, effectiveness, comparative clinical effectiveness, and appropriateness of pharmaceuticals … Food and Drug Administration [FDA], Health Canada, Japanese Pharmaceuticals and Medical Devices Agency … http://www.fda.gov/downloads/Drugs/Drug Safety/ucm089809.pdf. Accessed January 10, 2017. 21. … http://www.fda.gov/downloads/Drugs/Guida nces/ucm073122.pdf. Accessed January 10, 2017. 37. … /downloads/Drugs/DrugSafety/ucm089809.pdf http://www.wma.net/en/30publications/10policies/b3/ http://

373. Research White Paper Multinational Registries Addendum Registries for Evaluating Patient Outcomes Third Edition (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/multinational-registries-guide-3rd-ed-addendum-white-paper.pdf
     February 01, 2018 - focused on the outcomes, effectiveness, comparative clinical effectiveness, and appropriateness of pharmaceuticals … Food and Drug Administration [FDA], Health Canada, Japanese Pharmaceuticals and Medical Devices Agency … http://www.fda.gov/downloads/Drugs/Drug Safety/ucm089809.pdf. Accessed January 10, 2017. 21. … http://www.fda.gov/downloads/Drugs/Guida nces/ucm073122.pdf. Accessed January 10, 2017. 37. … /downloads/Drugs/DrugSafety/ucm089809.pdf http://www.wma.net/en/30publications/10policies/b3/ http://

374. 8 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/methodsguide_chou_assessing_harms_when_comparing.pdf
     November 01, 2008 - most regulatory approvals, and the source of most advertising and other claims made on behalf of drugs … For example, a systematic review of nonsteroidal anti-inflammatory drugs (NSAIDs) found cyclo-oxygenase … Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs … Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis … Causality assessment of adverse reactions to drugs—I.

375. 8 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-harms_methods.pdf
     November 01, 2008 - most regulatory approvals, and the source of most advertising and other claims made on behalf of drugs … For example, a systematic review of nonsteroidal anti-inflammatory drugs (NSAIDs) found cyclo-oxygenase … Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs … Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis … Causality assessment of adverse reactions to drugs—I.

376. Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin - Executive Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/evidence-summary-cer-199-skin-cancer.pdf
     December 01, 2017 - • Recurrence rates for SCC in situ were lower with PDT and cryotherapy than with drugs. … Adverse Events, All BCC Lesions In Table B drugs were most likely to have adverse events leading to … Conversely, use of topical drugs is generally limited to primary, superficial tumors. … Therefore, comparisons of the efficacy of radiation and drugs for the low-risk BCCs included in our … Adjuvant radiotherapy and new drugs (including epidermal growth factor receptor inhibitors, such as

377. Untitled (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-disease-ace-inhibitor-arb_surveillance.pdf
     July 06, 2015 - Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 … The primary goal of this review is to identify any missing studies, drugs, interventions, or devices … is needed to determine if ACE inhibitors or ARBs offer additional benefits over other vasoactive drugs … Since ONTARGET directly compared the same drugs as were evaluated in the placebo-controlled HOPE and … Since ONTARGET directly compared the same drugs as were evaluated in the placebo- controlled HOPE and

378. Systematic Review of Calcineurin Inhibitors for Kidney Transplant | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/calcineurin-inhibitor/research-protocol
     October 14, 2014 - amount of drug administered early or late post-transplant; 4) CNI avoidance, which substitutes other drugs … Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic … Pharmaceuticals. 2013;6(10):1170-94. Also available: https://dx.doi.org/10.3390/ph6101170 . … relies on antibodies binding to specific antigens; frequently used to measure levels of therapeutic drugs … in a biologic sample Nephrotoxicity: exposure of the kidneys to poisonous (toxic) chemicals; many drugs

379. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/antidepressants-2007_executive.pdf
     January 01, 2007 - Both drugs are produced by the same manufacturer, which funded all available studies. … The second- generation antidepressants cannot be considered identical drugs. … Evidence of moderate strength supports some differences among individual drugs with respect to onset … The incidence was 8-percent (95-percent CI, 3-11 percent) higher than with comparator drugs. … Mirtazapine led to higher weight gains than comparator drugs (fluoxetine, paroxetine, venlafaxine, and

380. Treatment for Restless Legs Syndrome: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/restless-legs-future_research.pdf
     February 01, 2013 - What is the effectiveness of approved RLS drugs on patient subgroups such as children, older adults … O 2 What is the effectiveness of other drugs that are not dopamine agonists or alpha 2 ligands (e.g. … Comparator Nontreatment, drugs, or nondrug therapies. … Nontreatment, drugs, or nondrug therapies. … • What is the effectiveness of other drugs that are not dopamine agonists or alpha 2 ligands (e.g.